In this exclusive roundtable report, leading experts discuss the evolving landscape and the latest strategies to address immunogenicity and safety challenges in oncology biologics and biosimilars, including:
- Streamlining immunogenicity assays from preclinical to clinical stages
- Navigating regulatory hurdles
- The growing role of AI and technology in targeted testing
- Balancing flexibility in neutralizing antibody assay selection